Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Gorgan University of Medical Sciences. 2017; 18 (4): 52-59
en Persa | IMEMR | ID: emr-189606

RESUMEN

Background and Objective: Lovastatin is a HMG-CoA reductase inhibitor and used for the treatment of hypercholesterolemia. Inhibition of HMG-CoA reductase results in inhibiting the activity of the Ras proto-oncogene that has mutations in most cancers. This study was done to determine the Anti-proliferative and apoptotic effects of Lovastatin on K562 Erthromyloidy cancer cell line


Methods: The K562 Erthromyloidy cancer cell line were cultured and treated with different concentrations of lovastatin. Their antitumor effect on K562 cells were assessed via MTT assay after 72 hours. Hoechst [33342] staining and DNA electrophoresis were used for study of apoptosis


Results: Lovastatin had antitumor effect on K562 Erthromyloidy cancer cell line and this effect increased by incease of time and concentration.The maximum inhibitory effect was 59% in higher concentration [100 M] and 72 hours after the treatment. Reduced cell growth at 24 and 48 hours after treatment was 24% and 43%, respectively. Lovastatin significantly inhibited K562 cell growth [P<0.05]


Conclusion: This study showed that lovastatin has antitumor effect on K562 Erthromyloidy cancer cell line


Asunto(s)
Leucemia Mielógena Crónica BCR-ABL Positiva , Línea Celular Tumoral , Células K562 , Apoptosis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA